Nashville, Tenn.-based eyecare pharmaceutical company Harrow has acquired the U.S. commercial rights to five FDA-approved ophthalmic medications from Novartis for $175 million.
Harrow acquires rights to 5 Novartis ophthalmology drugs for $175M
Nashville, Tenn.-based eyecare pharmaceutical company Harrow has acquired the U.S. commercial rights to five FDA-approved ophthalmic medications from Novartis for $175 million.